Trial record 8 of 11 for:    nicvax

Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Nabi Biopharmaceuticals
ClinicalTrials.gov Identifier:
NCT01178346
First received: August 5, 2010
Last updated: May 8, 2012
Last verified: May 2012
  Purpose

The purpose of this study is to look at pharmacoeconomic data for subjects that have received either NicVAX or placebo in the Nabi-4514 or Nabi-4515 studies.


Condition Intervention Phase
Smoking Cessation
Biological: NicVAX vaccine
Biological: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: Health-Related Quality-of-Life and Health-Care Resource Utilization Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies

Resource links provided by NLM:


Further study details as provided by Nabi Biopharmaceuticals:

Primary Outcome Measures:
  • To evaluate the effect of NicVAX vs. placebo on HRQoL over the study period. [ Time Frame: one year ] [ Designated as safety issue: No ]
    QoL and health utilization questionnaires will be used to measure this outcome.


Secondary Outcome Measures:
  • To estimate utility scores for use in further health-economic models. [ Time Frame: one year ] [ Designated as safety issue: No ]
    Scores will be computed from QoL questionnaires to measure this outcome.

  • To evaluate health care resource utilization. [ Time Frame: one year ] [ Designated as safety issue: Yes ]
    Health care visits, medications, hospitalizations and medical procedures will be collected to measure this outcome.


Enrollment: 500
Study Start Date: July 2010
Study Completion Date: November 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NicVAX
Experimental vaccine
Biological: NicVAX vaccine
NicVAX vaccine given 6 times over 6 months
Placebo Comparator: Placebo
Placebo vaccine
Biological: Placebo
Placebo vaccine given 6 times over 6 months

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects who are eligible for randomization or have not reached Week 12 in Nabi-4514 or Nabi-4515 studies.
  • Subjects who agree to participate in health-related quality of life study.

Exclusion Criteria:

  • Subjects who are unable to complete a HRQoL questionnaire because of inability to understand the language or due to mental impairment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01178346

  Show 25 Study Locations
Sponsors and Collaborators
Nabi Biopharmaceuticals
GlaxoSmithKline
Investigators
Study Director: Medical Monitor Nabi Biopharmaceuticals
  More Information

No publications provided

Responsible Party: Nabi Biopharmaceuticals
ClinicalTrials.gov Identifier: NCT01178346     History of Changes
Other Study ID Numbers: Nabi-4519
Study First Received: August 5, 2010
Last Updated: May 8, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Nabi Biopharmaceuticals:
Pharmacoeconomic
Quality of Life
Health Outcomes
Smoking
NicVAX
Smoking vaccine
Smoking cessation

ClinicalTrials.gov processed this record on September 14, 2014